Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.80 |
| ▸ | ESR2 | Q92731 | 17/20 | 0.80 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154281 | 0.91 | ESR1 (0.85) | ESR1ESR2PTGS2 | |
| SCHEMBL17154284 | 0.89 | ESR1 (1.00) | ESR1ESR2PTGS2 | |
| SCHEMBL17155585 | 0.88 | ESR1 (0.76) | ESR1ESR2LTA4HPTGS2 | |
| SCHEMBL12308318 | 0.87 | ESR1 (0.89) | ESR1ESR2PTGS2 | |
| SCHEMBL7457759 | 0.84 | ESR1 (0.85) | ESR1ESR2ENPP1 | |
| Hydrochloric Acid SCHEMBL7457698 | 0.83 | ESR1 (0.84) | ESR1ESR2ENPP1 | |
| SCHEMBL3743164 | 0.82 | ESR1 (1.00) | ESR1ESR2PTGS2 | |
| Hydrochloric Acid SCHEMBL3807019 | 0.82 | ESR1 (1.00) | ESR1ESR2PTGS2 | |
| SCHEMBL20442774 | 0.81 | ESR1 (0.66) | ESR1ESR2 | |
| SCHEMBL7517965 | 0.81 | ESR1 (0.98) | ESR1ESR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114052-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2017-04-27 | — | — | US | disclosed |
| US-20150284357-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284357-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, CYP19A1, ESR1 | ESR1 3/4885ESR2 5/4885LTA4H 1393/4885 |
| US-20170114052-A1 | COMPOSITIONS AND METHODS FOR TREATING ESTROGEN-RELATED MEDICAL DISORDERS | HSD17B11, CYP19A1, ESR1 | ESR1 3/4885ESR2 5/4885LTA4H 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.